For the past nearly 20 years, ANKASCIN 568-R has been proven by 120+ publications to be effective in managing blood lipids, blood sugar, blood pressure, and improving symptoms of Alzheimer’s disease through many animal tests conducted by Professor Tzu-Ming Pan from National Taiwan University, Taiwan.
This year, two randomized double-blind placebo-controlled clinical trials on ANKASCIN 568-R have been finalized by Dr. Chin-Kun Wang at Chung Shun Medical University, Taiwan. One of the clinical trials indicated that, after 8 weeks of administration, levels of serum cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were statistically significantly reduced by 11.1% and 20.4%, respectively. The other clinical trial showed that, after 12 weeks of administration, fasting blood glucose (FBG) levels were statistically significantly reduced by 9.3%. Clinical results further support previous animal tests, confirming that the two new active compounds (Monascin and Ankaflavin) contained in this ingredient are multi-effective. Adding these results, ANKASCIN 568-R has been completed in full aspects of health benefits, safety, legality, and identity for quality assurance.
